Sertraline: Nursing Drug Guide, Suicidality & Serotonin Syndrome

Sertraline is supplied as oral tablets, capsules, and a concentrated oral solution. Verify formulation, strength, and whether the patient takes once-daily continuous dosing or intermittent luteal-phase dosing for premenstrual dysphoric disorder (PMDD) on every administration pass.

Common U.S. brand example: Zoloft (sertraline tablets and oral solution). Generic sertraline hydrochloride is widely dispensed in 25 mg, 50 mg, and 100 mg tablet strengths and as a 20 mg/mL oral solution that must be diluted before administration.

• Tablet strengths: 25 mg, 50 mg, 100 mg per prescribing information
• Oral solution: 20 mg sertraline per mL (contains 12% alcohol); must be diluted; contraindicated with disulfiram because of alcohol content
• Look-alike name: Tall-man lettering SERtraline appears on some labels to reduce confusion with other psychotropics

Sertraline is indicated for major depressive disorder (MDD), obsessive-compulsive disorder (OCD), panic disorder (PD), post-traumatic stress disorder (PTSD), social anxiety disorder (SAD), and premenstrual dysphoric disorder (PMDD). Screen for bipolar disorder before starting antidepressant monotherapy—untreated depression carries suicide risk, but antidepressant monotherapy may precipitate mania in susceptible patients.

↔On a small screen, swipe or scroll sideways to see the full table.

Sertraline is a selective serotonin reuptake inhibitor (SSRI) that increases serotonergic activity in the central nervous system by inhibiting neuronal reuptake of serotonin. The exact mechanism linking serotonin reuptake inhibition to antidepressant and anxiolytic effects is not fully established in labeling.

Mean peak plasma concentrations occur approximately 4.5 to 8.4 hours after dosing; terminal elimination half-life is about 26 hours with roughly two-fold accumulation to steady state after one week of once-daily dosing. Nurses should not interpret lack of mood response in the first 1 to 2 weeks as treatment failure without prescriber review, and should treat any new serotonergic drug as a high-risk interaction even after a single missed dose.

Dosing depends on indication, age, hepatic function, and interacting drugs. Increase at intervals of not less than one week. Maximum doses vary by indication—institutional protocols and product formulations may vary.

Renal and hepatic adjustments

↔On a small screen, swipe or scroll sideways to see the full table.

MAOI switching (critical): At least 14 days between discontinuation of an MAOI antidepressant and initiation of sertraline, and at least 14 days after stopping sertraline before starting an MAOI antidepressant.

Missed dose: Take the missed dose as soon as remembered unless it is close to the next dose; do not double doses. If multiple doses are missed or serotonergic drugs are newly ordered, clarify with pharmacy before resuming.

Pretreatment checks

• Confirm indication, dose, formulation (tablet, capsule, or oral solution), and whether PMDD dosing is continuous or luteal-phase only
• Review for MAOI, linezolid, or methylene blue exposure within 14 days; screen for pimozide co-orders
• Perform medication reconciliation for serotonergic drugs (tramadol, triptans, other SSRIs/SNRIs, lithium, St. John’s wort)
• Assess suicide risk, psychiatric history, and bipolar disorder screening; involve caregivers for pediatric and young adult patients
• Review bleeding risk if patient takes warfarin, antiplatelets, or NSAIDs; check baseline sodium in older adults on diuretics when clinically ordered

Contraindications

• Concomitant MAOIs or use within 14 days of stopping MAOIs (including linezolid and IV methylene blue)
• Concomitant pimozide
• Known hypersensitivity to sertraline or excipients
• Oral solution with disulfiram (alcohol content in formulation)

Important interactions

↔On a small screen, swipe or scroll sideways to see the full table.

Route: Oral tablets (25, 50, 100 mg), capsules, or concentrated oral solution (20 mg/mL). May be taken with or without food; food causes a small increase in peak concentration without clinically significant effect on overall exposure.

• Give once daily at the same time each day unless intermittent PMDD luteal dosing is ordered
• Swallow tablets/capsules whole unless pharmacy approves alternative administration for swallowing difficulty
• For oral solution: dilute immediately before use per product instructions; contains 12% alcohol—do not give with disulfiram
• Verify strength before administration—100 mg tablets are high-strength units requiring independent double-check when used
• When switching from another antidepressant, confirm washout intervals with pharmacy—especially after fluoxetine, which requires longer MAOI spacing

• Gradual improvement in depressive and anxiety symptoms over several weeks—early partial response is common before full benefit
• Reduced panic attack frequency and anticipatory anxiety when used for panic disorder after titration
• Decreased obsessive-compulsive symptoms over weeks of consistent therapy in OCD
• Improved PTSD-related hyperarousal and mood symptoms with sustained dosing and trauma-informed care
• Stable mental status without new agitation, mania, or suicidality—therapeutic response must not come at the cost of activation or serotonin toxicity

Suicidality and serotonin syndrome are the two escalation pathways nurses must not miss. Discontinue sertraline and concomitant serotonergic agents immediately when serotonin syndrome is suspected and initiate supportive treatment per protocol.

• New or worsening suicidal ideation, self-harm behaviors, or sudden behavioral changes in pediatric or young adult patients—especially within the first months or after dose changes
• Mental status changes—agitation, hallucinations, delirium, or coma—especially after new tramadol, triptan, or linezolid
• Autonomic instability—tachycardia, labile blood pressure, hyperthermia, diaphoresis
• Neuromuscular hyperactivity—tremor, rigidity, myoclonus, hyperreflexia, incoordination
• Seizures, severe nausea/vomiting/diarrhea cluster with autonomic signs—treat as serotonin syndrome until ruled out
• Mania/hypomania, racing thoughts, or decreased need for sleep—hold and notify prescriber; may indicate bipolar activation
• Symptomatic hyponatremia—headache, confusion, weakness, unsteadiness; severe cases may include seizure or coma
• Severe rash, angioedema, or systemic allergic signs—stop permanently unless allergy service approves rechallenge

↔On a small screen, swipe or scroll sideways to see the full table.

Prescribing information does not list a specific reversal agent for sertraline overdose. Management is supportive, with activated charcoal considered in patients who present early after ingestion. Co-ingestion with other serotonergic drugs increases serotonin syndrome risk.

Reported overdose findings

• Seizures (may be delayed) and altered mental status including coma
• Cardiovascular toxicity (may be delayed)—QRS and QTc prolongation; hypertension most common; hypotension possible with co-ingestants including alcohol
• Serotonin syndrome—especially with multiple pro-serotonergic drugs

Supportive care

• Airway, breathing, circulation; cardiac monitoring for delayed QT and arrhythmias
• Consider gastrointestinal decontamination with activated charcoal when presentation is early
• Treat seizures and hyperthermia per emergency protocol; cooling measures for serotonin syndrome
• Discontinue sertraline and other serotonergic agents when toxicity is suspected

• SERtraline vs citalopram vs escitalopram—all are SSRIs with different interaction profiles; verify generic name on MAR
• Zoloft vs other “-ft” psychotropics—brand name confusion with unrelated drugs; confirm active ingredient
• Strength mix-ups—25 mg, 50 mg, and 100 mg tablets/capsules; 100 mg is a high unit dose
• Duplicate SSRI therapy—home sertraline plus newly ordered fluoxetine or escitalopram is a common reconciliation error
• Tablet vs oral solution—solution requires dilution and contains alcohol; do not substitute without pharmacy review
• MAOI / linezolid orders—antibiotic linezolid is an MAOI-class interaction; treat as contraindicated unless documented specialist plan with washout

↔On a small screen, swipe or scroll sideways to see the full table.

↔On a small screen, swipe or scroll sideways to see the full table.

Monitor

• Mental status, mood, anxiety level, and suicidal ideation—especially first few months and at dose changes in young patients
• Activation symptoms (insomnia, agitation, restlessness) that may precede improvement or signal toxicity
• Vital signs and neurologic exam when serotonergic drugs are added—screen for serotonin syndrome for hours after new doses
• Sodium trends in older adults, diuretic users, or patients with confusion or falls; electrolyte panel per prescriber when SIADH is suspected
• INR and bleeding signs when combined with warfarin or antiplatelet therapy; trend INR per anticoagulation protocol when ordered
• Weight in pediatric patients per labeling guidance

Document

• Indication, dose, formulation, and time of administration; PMDD schedule if intermittent
• Suicidality screening results and caregiver teaching for boxed-warning populations
• Serotonergic medication review and MAOI/linezolid washout verification when applicable
• Adverse effects, hold parameters communicated to prescriber/pharmacy, and patient response to teaching

• Take once daily at the same time; full benefit may take several weeks—do not stop abruptly without prescriber guidance
• Report worsening depression, suicidal thoughts, agitation, panic, irritability, or unusual behavior immediately—especially in the first months
• Seek urgent care for fever with agitation, severe tremor, muscle stiffness, or confusion—possible serotonin syndrome
• Avoid starting MAOI foods/drugs, St. John’s wort, or extra serotonergic medicines without prescriber approval
• Oral solution contains alcohol—do not take with disulfiram; avoid alcohol per medication guide
• Report easy bruising, black stools, or prolonged bleeding, especially if also taking blood thinners or NSAIDs

Do not give and contact the prescriber/pharmacist when:

Hold parameters may vary by institutional protocol. Follow prescriber orders, pharmacy guidance, and facility policy.

Practice NCLEX-style clinical judgment practice for sertraline using a tabbed case (MAR, labs, vitals, nursing notes), then priority action, cue recognition, trend interpretation, matrix urgency sorting, suicidality judgment, and documentation cloze—recognise cues → analyse → prioritise → act → evaluate outcomes around boxed-warning monitoring and serotonergic stacking.

This medication guide is written and reviewed using NurseOnShift editorial and clinical review standards.

• Editorial Policy
• Medical Review Process
• Disclaimer

Educational use only. This content does not replace clinical judgment, prescriber orders, pharmacist guidance, product labeling, or institutional protocols.